63459040430
Gabitril
Product Images NDC 68151-4235
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabitril (NDC 68151-4235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Structure (Image 01)
Figure01 (Image 02)
The text describes the percentage reduction in partial seizure rate for patients receiving Gabitril compared to placebo. The data is displayed using a graph with 100%, 50%, and 0% as the vertical axis and Gabitril and placebo as the horizontal axis. The graph also shows the percentage of patients who experienced improvement, no change, or worsening.*
Figure02 (Image 03)
The text represents a chart that shows the reduction in partial seizure rate achieved by using different dosages of GABITRIL. The chart includes four percentage values, three dosage values and three dosage labels. It also includes labels for the percentage of patients who experienced improvement, no change or worsening.*
Figure03 (Image 04)
This is a graph showing the % reduction in partial seizure rate achieved with different doses of GABITRIL compared to placebo. The vertical axis shows % of patients, while the horizontal axis shows improvement (left side), no change (middle), and worsening (right side). The graph suggests that GABITRIL, even at low doses, was more effective in reducing partial seizures than placebo in this study.*
Figure04 (Image 05)
The text appears to be a graph or chart displaying the percentage reduction in partial seizure rate for patients taking a placebo versus those taking GABITRL 10 mg TD. The graph shows percentage values ranging from -250% to 100%. The x-axis or horizontal axis shows the percentage of patients, while the y-axis or vertical axis shows the level of improvement (in percentage). The graph indicates a significant reduction in partial seizure rate for patients taking GABITRL 10 mg TD.*
Tevalogo.jpg (Image 10)
Label Image (Lbl681514235)
GABITRIL is a medication manufactured by Cephalon that contains 4mg tiagabine HCL tablets. The lot number is GB30312 and the expiration date is 07/14. The product code is W0104145N30 and it is available with a prescription (RX Only).*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
